On September 29, Gelonhui reported that pacific shuanglin bio-pharmacy (000403.SZ) conducted an investor survey on September 26, 2024, regarding” the acceptance of the existing plasma stations and the expansion plan of new plasma stations?. The company stated that regarding the acceptance of plasma stations: up to now, the company has a total of 38 plasma stations, paisifei 19 plasma stations, 17 plasma stations are in operation for plasma collection, and 2 plasma stations have been completed and are applying for acceptance, it is expected to complete the acceptance before the end of this year; guangdong shuanglin has 19 plasma stations, 17 plasma stations are in operation for plasma collection, and 2 plasma stations have been completed and are actively applying for acceptance.

Regarding the expansion of new plasma stations: because the scale of raw plasma determines the scale of blood product companies, the company attaches great importance to the expansion of new plasma stations. The company will actively promote the expansion of new plasma stations with the help of shareholders and various resources and forces. As of now, the company has already obtained county-level and municipal-level approvals in some areas, striving to achieve a breakthrough as soon as possible. Please refer to the specific disclosures of the listed company for details.